Acurx Pharmaceuticals, Inc.

  • Home
  • About
    • Management / Consultants
    • Scientific / Corporate Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • Ibezapolstat
    • GPSS®
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Videos
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

ALERT: NEW ARTICLE

New England Journal of Medicine , “One Pivotal Trial, the New Default Option for FDA Approval – Ending the Two-Trial Dogma,” by Vinay Prasad, M.D., M.P.H.1 and Martin A. Makary, M.D., M.P.H.1

Read Publication

Continue

Presentations

News & Media

News & Media

  • Press Releases
  • Presentations
  • Videos
DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile

Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile

Scientific Presentation

In Vitro Activity of the Novel Antibacterial ACX-362E against Clostridioides difficile

In Vitro Activity of the Novel Antibacterial ACX-362E against Clostridioides difficile

Scientific Presentation

RSS
  • « Previous
  • 1
  • 2
  • 3
© 2026 Acurx Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap